RTW Investments LP purchased a new stake in Fluidigm Co. (NASDAQ:FLDM) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 884,235 shares of the medical research company’s stock, valued at approximately $7,622,000. RTW Investments LP owned 2.25% of Fluidigm as of its most recent SEC filing.
Other hedge funds have also modified their holdings of the company. Quantamental Technologies LLC purchased a new position in Fluidigm in the 4th quarter valued at approximately $61,000. United Services Automobile Association purchased a new stake in shares of Fluidigm during the 4th quarter worth $102,000. Brown Advisory Inc. purchased a new stake in shares of Fluidigm during the 4th quarter worth $115,000. Bank of America Corp DE lifted its position in shares of Fluidigm by 149.3% during the 4th quarter. Bank of America Corp DE now owns 14,449 shares of the medical research company’s stock worth $125,000 after purchasing an additional 8,654 shares during the last quarter. Finally, Rhumbline Advisers lifted its position in shares of Fluidigm by 42.9% during the 4th quarter. Rhumbline Advisers now owns 34,489 shares of the medical research company’s stock worth $297,000 after purchasing an additional 10,358 shares during the last quarter.
Shares of Fluidigm stock traded up $0.10 during trading on Monday, hitting $13.69. 5,492 shares of the stock were exchanged, compared to its average volume of 956,891. The stock has a market cap of $937.92 million, a P/E ratio of -17.00 and a beta of 2.40. Fluidigm Co. has a 12-month low of $4.65 and a 12-month high of $14.90. The company has a current ratio of 3.38, a quick ratio of 3.04 and a debt-to-equity ratio of 2.39.
Several research firms have recently issued reports on FLDM. BidaskClub raised shares of Fluidigm from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 16th. UBS Group began coverage on shares of Fluidigm in a research report on Friday, March 15th. They set a “neutral” rating and a $14.00 price objective for the company. BTIG Research began coverage on shares of Fluidigm in a research report on Wednesday, March 13th. They set a “buy” rating and a $15.00 price objective for the company. Piper Jaffray Companies lifted their price objective on shares of Fluidigm from $10.00 to $14.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 13th. Finally, Zacks Investment Research raised shares of Fluidigm from a “strong sell” rating to a “buy” rating and set a $13.00 price objective for the company in a research report on Tuesday, March 5th. Two analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. Fluidigm currently has an average rating of “Buy” and a consensus target price of $14.00.
COPYRIGHT VIOLATION WARNING: This story was first published by Dakota Financial News and is the property of of Dakota Financial News. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://dakotafinancialnews.com/2019/03/25/rtw-investments-lp-purchases-new-stake-in-fluidigm-co-fldm.html.
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system.
Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.